Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled adjuvant SH-1028 trial in EGFR-mutant resected stage II-IIIB non-small cell lung cancer
CTR20223093Phase 3Active
- Sponsor
- Shenghe Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Shenghe Pharmaceutical. Started Dec 2022; status: active.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223093.